Allakos, Inc.

55 articles with Allakos, Inc.

• Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/6/2023

  Allakos Inc. today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.

• Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

  11/29/2022

  Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the publication of “Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells,” in Communications Biology.

• Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

  11/10/2022

  Allakos Inc. inflammatory and proliferative diseases, today announced a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.

• Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results

  11/7/2022

  Allakos Inc., a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, provided a business update and reported financial results for the third quarter ended September 30, 2022.

• Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock

  9/19/2022

  Allakos Inc. today announced the pricing of an underwritten offering of 29,882,000 shares of its common stock at an offering price of $5.02 per share.

• Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis

  9/9/2022

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today reported data from EoDyssey, a 24-week, Phase 3, randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic duodenitis (EoD).

• Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

  8/4/2022

  Allakos Inc., a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, provided a business update and reported financial results for the second quarter ended June 30, 2022.

• Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

  7/25/2022

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors.

• Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

  5/6/2022

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.

• Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

  3/1/2022

  Allakos Inc., a biotechnology company developing lirentelimab and AK006 for the treatment of allergic and inflammatory diseases, provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021.

• Allakos to Host Investor Day on February 15

  2/1/2022

  Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, announced that it will host an Investor Day on February 15th starting at 8:00 am ET.

• 

  Allakos Reports Mixed Results for Two Eosinophilic GI Disease Studies

  12/22/2021

  Allakos reported mixed results on two clinical trials, the Phase II ENIGMA 2 and Phase II/III KRYPTOS trials of lirentelimab.

• Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal Diseases

  12/21/2021

  Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), today reported data from ENIGMA 2, a 24-week Phase 3 randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and KRYPTOS, a 24-week Phase 2/3 randomized, double-blind, placebo-controlled study of lirentelimab.

• Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma

  11/30/2021

  Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced it has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial of subcutaneous (SC) lirentelimab in adult patients with moderate-to-severe atopic dermatitis.

• Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results

  11/8/2021

  Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2021.

• Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation

  10/25/2021

  Allakos Inc. today announced that its poster, “High Discovery Rate of Eosinophilic Gastritis and/or Duodenitis Among Patients with Chronic Unexplained Gastrointestinal Symptoms,” received a Presidential Poster Award at the American College of Gastroenterology (ACG) 2021 Annual Scientific Meeting.

• Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting

  10/24/2021

  Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell related diseases, announced the acceptance of six poster presentations at the upcoming American College of Gastroenterology Annual Scientific Meeting.

• Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results

  8/9/2021

  Allakos Inc.Allakos Inc.Allakos Inc.Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, provided a business update and reported financial results for the second quarter ended June 30, 2021.

• New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms

  5/24/2021

  45% (181/405) of patients with chronic functional gastrointestinal symptoms who underwent upper endoscopy with biopsy met the diagnostic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD)

• Allakos Reports First Quarter 2021 Financial Results and Provides Business Update

  5/10/2021

  Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, reported financial results for the first quarter ended March 31, 2021 and provided a business update.